38185066|t|A new andrographolide derivative ADA targeting SIRT3-FOXO3a signaling mitigates cognitive impairment by activating mitophagy and inhibiting neuroinflammation in Apoe4 mice.
38185066|a|BACKGROUND: Alzheimer's disease (AD) is one of the most common neurodegenerative diseases and mitophagy deficit was identified as the typical abnormality in early stage of AD. The neuroprotective effect of andrographolide (AGA) has been confirmed, anda acetylated derivative of AGA (3,14,19-triacetylandrographolide, ADA) was considered to have stronger efficacy. PURPOSE: The current study aims to investigate the impact of ADA on cognitive ability in a sporadic AD model and explore its potential mechanism. STUDY DESIGN/ METHODS: Apoe4 mouse was adopted for evaluating the impact of AGA on cognitive impairment through a serious of behavioral tests. The molecular mechanism of ADA involved in mitophagy and neuroinflammation was investigated in detailby Western blot, ELISA, immunofluorescence and transmission electron microscopy in Apoe4 mice, as well as Apoe4-transfected BV2 cells and HT22 cells. RESULTS: ADA application significantly improved cognitive impairment of Apoe4 mice, and lessened Abeta load and neuronal damage, which has stronger activity than its prototype AGA. Accumulated mitophagy markers LC3II, P62, TOM20, PINK1 and Parkin, and decreased mitophagy receptor BNIP3 in hippocampus of Apoe4 mice were greatly reversed after ADA treatment. Meanwhile, ADA promoted the recruitment of BNIP3 to mitochondria, and the transport of damaged mitochondria to lysosome, indicating that disturbed mitophagy in AD mice was restored by ADA. Inhibited SIRT3 and FOXO3a in Apoe4 mice brains were elevated after ADA treatment. ADA also lightened the neuroinflammation caused by NLRP3 inflammasome activation. Additionally, damaged mitophagy and/or activated NLRP3 inflammasome were also observed in BV2 cells and HT22 cells transfected with Apoe4, all of which were rescued by ADA incubation. Noteworthily, SIRT3 inhibitor 3-TYP could abolish the impact of ADA on mitophagy and NLRP3 inflammasome in vitro. CONCLUSION: ADA exerted stronger cognition-enhancing ability in relative to AGA, and ADA could repaire mitophagy deficiency via SIRT3-FOXO3a pathway, and subsequently inhibite NLRP3 inflammasome to mitigate AD pathology.
38185066	6	21	andrographolide	Chemical	MESH:C030419
38185066	33	36	ADA	Gene	11486
38185066	47	52	SIRT3	Gene	64384
38185066	53	59	FOXO3a	Gene	56484
38185066	80	100	cognitive impairment	Disease	MESH:D003072
38185066	140	157	neuroinflammation	Disease	MESH:D000090862
38185066	167	171	mice	Species	10090
38185066	185	204	Alzheimer's disease	Disease	MESH:D000544
38185066	206	208	AD	Disease	MESH:D000544
38185066	236	262	neurodegenerative diseases	Disease	MESH:D019636
38185066	277	284	deficit	Disease	MESH:D009461
38185066	345	347	AD	Disease	MESH:D000544
38185066	379	394	andrographolide	Chemical	MESH:C030419
38185066	396	399	AGA	Chemical	MESH:C030419
38185066	451	454	AGA	Chemical	MESH:C030419
38185066	456	488	3,14,19-triacetylandrographolide	Chemical	-
38185066	490	493	ADA	Gene	11486
38185066	598	601	ADA	Gene	11486
38185066	637	639	AD	Disease	MESH:D000544
38185066	712	717	mouse	Species	10090
38185066	759	762	AGA	Chemical	MESH:C030419
38185066	766	786	cognitive impairment	Disease	MESH:D003072
38185066	853	856	ADA	Gene	11486
38185066	883	900	neuroinflammation	Disease	MESH:D000090862
38185066	1016	1020	mice	Species	10090
38185066	1051	1054	BV2	CellLine	CVCL:0182
38185066	1065	1069	HT22	CellLine	CVCL:0321
38185066	1086	1089	ADA	Gene	11486
38185066	1125	1145	cognitive impairment	Disease	MESH:D003072
38185066	1155	1159	mice	Species	10090
38185066	1174	1179	Abeta	Gene	14961
38185066	1189	1204	neuronal damage	Disease	MESH:D009410
38185066	1253	1256	AGA	Chemical	MESH:C030419
38185066	1295	1298	P62	Gene	18226
38185066	1300	1305	TOM20	Gene	67952
38185066	1307	1312	PINK1	Gene	68943
38185066	1358	1363	BNIP3	Gene	12176
38185066	1388	1392	mice	Species	10090
38185066	1421	1424	ADA	Gene	11486
38185066	1447	1450	ADA	Gene	11486
38185066	1479	1484	BNIP3	Gene	12176
38185066	1596	1598	AD	Disease	MESH:D000544
38185066	1599	1603	mice	Species	10090
38185066	1620	1623	ADA	Gene	11486
38185066	1635	1640	SIRT3	Gene	64384
38185066	1645	1651	FOXO3a	Gene	56484
38185066	1661	1665	mice	Species	10090
38185066	1693	1696	ADA	Gene	11486
38185066	1708	1711	ADA	Gene	11486
38185066	1731	1748	neuroinflammation	Disease	MESH:D000090862
38185066	1759	1764	NLRP3	Gene	216799
38185066	1839	1844	NLRP3	Gene	216799
38185066	1880	1883	BV2	CellLine	CVCL:0182
38185066	1894	1898	HT22	CellLine	CVCL:0321
38185066	1958	1961	ADA	Gene	11486
38185066	1988	1993	SIRT3	Gene	64384
38185066	2004	2009	3-TYP	Chemical	-
38185066	2038	2041	ADA	Gene	11486
38185066	2059	2064	NLRP3	Gene	216799
38185066	2100	2103	ADA	Gene	11486
38185066	2164	2167	AGA	Chemical	MESH:C030419
38185066	2173	2176	ADA	Gene	11486
38185066	2216	2221	SIRT3	Gene	64384
38185066	2222	2228	FOXO3a	Gene	56484
38185066	2264	2269	NLRP3	Gene	216799
38185066	2295	2297	AD	Disease	MESH:D000544
38185066	Association	MESH:D003072	56484
38185066	Positive_Correlation	11486	56484
38185066	Association	MESH:D003072	64384
38185066	Negative_Correlation	MESH:D003072	11486
38185066	Negative_Correlation	MESH:C030419	MESH:D003072
38185066	Association	56484	64384
38185066	Negative_Correlation	11486	14961
38185066	Association	MESH:D000090862	64384
38185066	Association	MESH:D000090862	216799
38185066	Negative_Correlation	MESH:D000090862	11486
38185066	Association	MESH:C030419	64384
38185066	Negative_Correlation	11486	68943
38185066	Negative_Correlation	11486	12176
38185066	Association	MESH:C030419	11486
38185066	Association	MESH:D000544	11486
38185066	Positive_Correlation	11486	216799
38185066	Negative_Correlation	11486	67952
38185066	Association	MESH:D000090862	56484
38185066	Negative_Correlation	11486	18226
38185066	Positive_Correlation	11486	64384
38185066	Negative_Correlation	MESH:C030419	MESH:D000090862
38185066	Association	MESH:C030419	56484
38185066	Negative_Correlation	MESH:D009410	11486

